COVID-19 March 24, 2020 Federal Update

Legislation
Supplemental III – “COVID-III”

The hope continues to be that a deal can come together, that a time agreement can be reached, and that the Senate can vote expeditiously – if not yesterday night, then certainly by today. Absent any deal, the Senate would vote on cloture on the motion to proceed to the COVID-III vehicle one hour after convening tomorrow.

If the Senate passes the package today, the House could pass by unanimous consent on Thursday. If unanimous consent isn’t achievable, the fallback is the suspension calendar on Friday. All of this is dependent on how quickly a deal is reached and text is released.


Process and Politics:

Multiple caucus conference calls were held yesterday and it seems that both caucuses are attempting to marshal their members toward acceptance of passing the bill by unanimous consent in the House. Speaker Pelosi and other House leadership have indicated they would be willing to pass the bill in the House under unanimous consent, but only if the end product is acceptable.


Policy:

Multiple updated drafts of the bill have been circulated yesterday. However, it’s unclear as of right now, as negotiations are still ongoing, what provisions in the draft bill are completely set and what is being further negotiated. As with previous big deals, nothing is final until everything is final . All policies previously discussed continue to be on the table and could be part of a final deal. CARES text (as of earlier today) here. Latest information indicates a final bill may include the following:

  • $1,200 in direct payments, $500 per child with income limitations and restriction;
  • Early withdrawals from retirement accounts without penalty;
  • Expansion of unemployment insurance (includes eligibility to self-employed, contract employees) for 4 months;
  • Delay in payroll taxes by one year, payable over two years;
  • Net Operating Loss from tax years 2018, 2019, or 2020 may be carried back five years;
  • Small business bridge loans to companies with 500 employees or fewer with a maximum loan of $10 million, administered by 7(a) lenders;
  • $100 billion for hospitals with $50 billion in extra support for combatting COVID-19;
  • Expansion of HSAs to cover over the counter medicine;
  • Telehealth flexibility;
  • Suspension of the Medicare sequester through December 31, 2020. 
  • Liability protections for doctors practicing across state lines;
  • Treasury-administered loans for distressed industries, including $50 billion for passenger airlines, $8 billion for cargo carriers, $10 billion for AIP, with restrictions and a certain amount of oversight (unclear what that is until we see text).

Passed Legislation

Supplemental II – Families First Coronavirus Response Act (HR 6201)

The Senate passed the bill 90-8 Wednesday afternoon and the President signed the bill into law that evening. Bill text here. Factsheet here. Bill section by section here. A summary of paid leave provisions, incorporating changes made by technical correction, is  here.

Supplemental I – Coronavirus Supplemental

Signed by the President March 6. Text here , summary here.


Members of Congress in Quarantine or Treatment

Tested Positive (3): Sen. Rand Paul (R-KY), Rep. Ben McAdams (D-UT), Rep. Mario Diaz-Balart (R-FL)

Currently Self-Quarantined (26): Rep. Paul Gosar (R-AZ), Rep. Julia Brownley (D-CA), Rep. Jason Crow (D-CO), Rep. Matt Gaetz (R-FL), Rep. Mario Diaz-Balart (R-FL), Rep. Doug Collins (R-GA), Rep. Steve Scalise (R-LA), Rep. Ann Wagner (R-MO), Rep. Sharice Davids (D-KS), Rep. Ben Ray Luján (D-NM), Rep. Kathleen Rice (D-NY), Rep. Kendra Horn (D-OK), Rep. Matt Cartwright (D-PA), Rep. Ben McAdams (D-UT), Rep. Gwen Moore (D-WI), Rep. Frederica Wilson (D-FL), Rep. Stephanie Murphy (D-FL), Rep. Drew Ferguson (R-GA), Rep. Joe Cunningham (D-SC), Rep. Tom Cole (R-OK), Rep. David Schweikert (R-AZ), Rep. Anthony Brindisi (D-NY), Rep. David Price (D-NC), Rep. Andy Kim (D-NJ), Sen. Rick Scott (R-FL), Sen. Cory Gardner (R-CO), Sen. Mike Lee (R-UT), Sen. Mitt Romney (R-UT)

Completed Quarantine (4): Sen. Ted Cruz (R-TX), Rep. Mark Meadows (R-NC), Sen. Lindsay Graham (R-SC), Rep. Don Beyer (D-VA)

By Sheran Brown June 17, 2025
This week marks an important milestone for workforce development in the U.S. life sciences sector: the official launch of the Life Sciences Workforce Collaborative (LSWC) . Formerly known as the Coalition of State Bioscience Institutes (CSBI) , LSWC premiered at the 2025 BIO International Convention as a new national nonprofit—building on over a decade of state and regional leadership to expand industry-aligned solutions for talent development. As the life sciences industry confronts evolving technologies, shifting economic headwinds, and persistent workforce challenges - including specialized talent needs, unmet demand for skilled biomanufacturers, positioning for future growth —LSWC offers a unified platform to scale solutions, support workforce readiness, and strengthen public-private partnerships across the country. Just out of the gate, the new organization is pleased to announce a major insight-driven release later this month: the upcoming 2025 National Life Sciences Workforce Trends Report , produced in partnership with TEConomy Partners and the NSF-funded InnovATEBIO National Biotech Education Center . Comprised of data from over 700 life science companies and 2.9 million job postings, the report will go live on June 24, 2025. Why This Matters The newly launched LSWC builds on more than a decade of trusted collaboration among 50+ state, regional and national life science organizations and workforce partners. Its mission: to align, advise, and accelerate talent development efforts across the entire life sciences talent pipeline—from middle school to mid-career--to build a competitive life sciences workforce. Next week, the LSWC will launch the 2025 National Workforce Trends Report, the organization’s flagship effort. Now in its seventh edition, this biennial report draws on: Responses from over 500 companies across 30 states and Puerto Rico Interviews with over 200 life science executives Analysis of 2.9 million unique job postings across the U.S. from the last four years The report is the definitive source for understanding the real-world trends shaping hiring, upskilling, and STEM education engagement across the life sciences ecosystem. More to come next week. What Comes Next In the weeks ahead, we’ll be working with our partners to roll out media toolkits, schedule events, and activate coordinated campaigns to bring visibility to both the LSWC launch and the report. We are deeply grateful to our investor-level supporters—AZBio/AZ Advances, BioNJ, BioUtah, California Life Sciences, Georgia Life Sciences/Institute, Colorado Bioscience Association/Institute, MichBio, NewYorkBIO/Institute, Ohio Life Sciences, Oregon Bioscience Association, SCbio, and Southern California Biomedical Council (SoCalBio)—LSWC partners and connectors, and to every organization that has shaped this initiative from the ground up. Together, we are building a stronger, competitive, and future-ready workforce—one that ensures the U.S. remains the global leader in biotechnology, biomanufacturing, and life sciences innovation. Stay tuned and learn how you can partner with us to advance the life sciences workforce. Learn more at: www.LifeSciencesWorkforce.org For media inquiries: connect@lifesciencesworkforce.org
By Sheran Brown June 16, 2025
GLS has been named a new Spoke Member of the ARPA‑H Customer Experience Hub—ARPA‑H’s patient‑centric network dedicated to embedding real-world user insights and representation into health innovation. As part of the nationwide ARPANET‑H hub‑and‑spoke initiative (with hubs in Dallas, Boston, and D.C.), Georgia Life Sciences will help prioritize inclusive design, usability testing, and equitable trial participation in next-gen therapies.
By Sheran Brown June 10, 2025
June 9, 2025
MORE POSTS